SI2400954T1 - Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli - Google Patents

Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli

Info

Publication number
SI2400954T1
SI2400954T1 SI201031356A SI201031356A SI2400954T1 SI 2400954 T1 SI2400954 T1 SI 2400954T1 SI 201031356 A SI201031356 A SI 201031356A SI 201031356 A SI201031356 A SI 201031356A SI 2400954 T1 SI2400954 T1 SI 2400954T1
Authority
SI
Slovenia
Prior art keywords
solifenacin
pharmaceutically acceptable
acceptable salts
dosage forms
oral dosage
Prior art date
Application number
SI201031356A
Other languages
English (en)
Inventor
Miha Vrbinc
Franc Vrecer
Urska Turk
Urska Jursic
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42041747&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2400954(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of SI2400954T1 publication Critical patent/SI2400954T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201031356A 2009-02-27 2010-03-01 Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli SI2400954T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SI200900056 2009-02-27
SI200900159 2009-06-08
EP10705984.2A EP2400954B1 (en) 2009-02-27 2010-03-01 Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
PCT/EP2010/001262 WO2010097243A2 (en) 2009-02-27 2010-03-01 Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
SI2400954T1 true SI2400954T1 (sl) 2017-02-28

Family

ID=42041747

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031356A SI2400954T1 (sl) 2009-02-27 2010-03-01 Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli

Country Status (9)

Country Link
EP (1) EP2400954B1 (sl)
DK (1) DK2400954T3 (sl)
EA (1) EA023529B1 (sl)
ES (1) ES2609061T3 (sl)
HR (1) HRP20161730T1 (sl)
HU (1) HUE030376T2 (sl)
PL (1) PL2400954T3 (sl)
SI (1) SI2400954T1 (sl)
WO (1) WO2010097243A2 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137877A2 (en) * 2010-05-07 2011-11-10 Zentiva K.S. A pharmaceutical composition containing solifenacin and a method of its manufacture
EP2500013B1 (en) 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR20150092385A (ko) * 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
CN104940152B (zh) * 2014-03-31 2017-12-29 成都国为生物医药有限公司 一种含有琥珀酸索利那新的药物组合物
CN105012961B (zh) * 2014-04-17 2020-07-21 燃点(南京)生物医药科技有限公司 稳定的药物组合物及其制备方法
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
CN105362245A (zh) * 2014-08-30 2016-03-02 山东中泰药业有限公司 含有索利那新的片剂组合物及其制备方法
CN104523628B (zh) * 2014-12-24 2017-08-25 乐普药业股份有限公司 一种可粉末直接压片的琥珀酸索利那新片剂及其制备方法
EP3331503A1 (en) * 2015-08-05 2018-06-13 Interquim, S.A. Rivaroxaban pharmaceutical compositions
CN105395494A (zh) * 2015-11-27 2016-03-16 浙江华义医药有限公司 一种含琥珀酸索利那新的药物组合物及其制备方法
JP7222244B2 (ja) * 2017-08-08 2023-02-15 三菱ケミカル株式会社 医薬錠剤、およびその製造方法
KR101977890B1 (ko) * 2018-05-08 2019-05-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU508480B2 (en) 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
CZ23088U1 (cs) 2004-03-25 2011-12-19 Astellas Pharma Inc. Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
WO2007072169A2 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
WO2008013851A2 (en) * 2006-07-24 2008-01-31 Teva Pharmaceutical Industries Ltd. Processes for preparing polymorphic forms of solifenacin succinate
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
EP2018850A1 (en) 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
WO2010012459A2 (en) * 2008-07-29 2010-02-04 Krka, D.D., Novo Mesto A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms

Also Published As

Publication number Publication date
EA201190161A1 (ru) 2012-02-28
ES2609061T3 (es) 2017-04-18
EA023529B1 (ru) 2016-06-30
HRP20161730T1 (hr) 2017-02-24
HUE030376T2 (en) 2017-05-29
EP2400954B1 (en) 2016-09-28
WO2010097243A3 (en) 2011-06-16
EP2400954A2 (en) 2012-01-04
DK2400954T3 (en) 2017-01-16
WO2010097243A2 (en) 2010-09-02
PL2400954T3 (pl) 2017-04-28

Similar Documents

Publication Publication Date Title
PL2400954T3 (pl) Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2499147A4 (en) IMPROVED METHODS FOR THE PRODUCTION OF PRASUGREL AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
HK1220902A1 (zh) 族群抑制劑之口服醫藥劑型
PT2588090T (pt) Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveis
SI3363797T1 (sl) Peroralna farmacevtska oblika zaviralcev kinaze, ki uravnava signal apoptoze
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
SI2241553T1 (sl) Postopek za sintezo ivabradina in njegovih farmacevtsko sprejemljivih kislih dodatnih soli
IL223311A0 (en) Oral dosage forms of bendamustine
SI2736909T1 (sl) Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli
EP2435052A4 (en) SOLID PHARMACEUTICAL FORMS OF LAMIVUDIN ORAL ADMINISTRATION
SI2536396T1 (sl) Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
PL2241554T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem dopuszczalnym farmaceutycznie
EP2121729A4 (en) PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF
SI2585051T1 (sl) Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
SI2451809T1 (sl) Postopek za pripravo in čiščenje soli solifenacina
EP2389360A4 (en) METHOD FOR PRODUCING ZOFENOPRIL AND PHARMACEUTICAL ACCEPTIC SALTS THEREFOR
PL2607354T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
ME02391B (me) Postupak za prečišćavanje farmaceutski prihvatljivih soli escitaloprama
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof